Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University (Other)

Overall Status

Recruiting

CT.gov ID

NCT04706936

Collaborator

Carbiogene Therapeutics Co. Ltd. (Industry)

Enrollment

Location

Arm

Anticipated Duration (Months)

0.7

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This study evaluates the safety and efficacy of novel BCMA-targeted CAR-T cell therapy (CBG-002) for patients with relapsed or refractory multiple myeloma (r/r MM). CBG-002 is designed based on the fourth-generation of CAR-T techonology.

Condition or Disease	Intervention/Treatment	Phase
Relapsed or Refractory Multiple Myeloma	Biological: anti-BCMA CAR-T Drug: Cyclophosphamid Drug: Fludarabine	Phase 1

Study Design

Study Type:

Interventional

Anticipated Enrollment :

25 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma

Actual Study Start Date :

Apr 1, 2021

Anticipated Primary Completion Date :

Oct 1, 2022

Anticipated Study Completion Date :

Apr 1, 2024

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Anti-BCMA CAR-T (CBG-002) All subjects were intravenous administrated with CBG-002.	Biological: anti-BCMA CAR-T Retroviral vector-transduced autologous T cells to express anti-BCMA CAR. Other Names: CBG-002 CAR-T Drug: Cyclophosphamid 300mg/m2/d Drug: Fludarabine 30mg/m2/d

Arm

Intervention/Treatment

Experimental: Anti-BCMA CAR-T (CBG-002)

All subjects were intravenous administrated with CBG-002.

Biological: anti-BCMA CAR-T

Retroviral vector-transduced autologous T cells to express anti-BCMA CAR.

Other Names:

CBG-002 CAR-T

Drug: Cyclophosphamid

300mg/m2/d

Drug: Fludarabine

30mg/m2/d

Outcome Measures

Primary Outcome Measures

Rate of grade 3 or 4 treatment related adverse effect [24 weeks after last dose of CAR-T treatment]
All the CAR-T treatment related adverse events，including Dose limiting toxicity (DLT), cytokine release syndrome (CRS), CAR-T associated encephalopathy syndrome, will be assessed and graded by NCI CTCAE v 5.0.
Overall response rate (ORR) after treated by CAR-T treatment [up to 2 years after CAR-T treatment]
ORR will be assessed and graded by the international Myeloma Working Group (IMWG) Unified response criteria for multiple myeloma

Secondary Outcome Measures

Pharmacokinetics of CAR-T cells (implantation endpoint) [up to 2 years after CAR-T treatment]
To assess the duration of CAR-positive T cells in circulation, the copy number of CAR DNA was measured at the preset follow-up time point. The time when the results of any two consecutive tests were negative, were recorded as the "implantation endpoint".
Overall survival [up to 2 years after CAR-T treatment]
From date of inclusion to date of progression, relapse, or death from any cause.
Progression free survival [up to 2 years after CAR-T treatment]
The length of time that a participant's disease did not progress during and after CAR-T treatment.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 75 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Patients with relapsed/refractory multiple myeloma aged 18-75 years;
IHC or bone marrow samples confirmed by flow cytometry-plasma cell membrane is positive for BCMA expression;
Relapsed/refractory patients who meet the following conditions:
Ineffective or disease progression after receiving bortezomib (proteasome inhibitor) and lenalidomide for 3 courses;
Ineffective or disease progression after receiving the original treatment plan for 3 courses;
The interval between the last treatment and disease progression is more than 30 days;
There is currently no indication for hematopoietic stem cell transplantation, or the patient refuses to do hematopoietic stem cell transplantation;
The definition of disease progression refers to the "2014 IMWG Standards", and at least meets the following 1 items:

e.1 Serum M protein ≥ 0.5 g/dL;

e.2 Urine M protein ≥ 200 mg/24 h;

e.3 If the serum FLC ratio is abnormal, the patient's FLC level ≥ 10 mg/dL (100 mg/L);

e.4 Evaluable plasmacytoma confirmed by biopsy;

e.5 Increase in the proportion of bone marrow plasma cells ≥25% (absolute increase ≥10%);

e.6 Bone marrow plasma cells account for 30% of the total bone marrow cells;

Estimated survival time> 12 weeks;
The disease status can be assessed and meet at least one of the following:
Serum M-protein ≥10 g/L;
24h urine M-protein ≥200mg;
Serum FLC≥5mg/dL;
Plasma cell tumors that can be assessed by testing or images;
The proportion of bone marrow plasma cells ≥ 30%;
ECOG physical status score 0-1;
Have enough venous access for apheresis or venous blood collection, and there are no other contraindications for blood cell separation;
WBC ≥ 1.5×109/L; PLT ≥ 45×109/L;
Serum creatinine ≤ 1.5 upper limit of normal (ULN) (excluding patients with myeloma nephropathy);
ALT ≤ 2.5 ULN, AST ≤ 2.5 ULN.

All laboratory test results within the above range should have no ongoing continuous supportive treatment.

Exclusion Criteria:

Subjects who meet any of the following criteria cannot be selected for this study:

Systemic treatment such as lymphatic depletion with cyclophosphamide and fludarabine within 2 weeks before enrollment or single cell collection, or cell therapy within 8 weeks before treatment;
HCV or HIV positive; any uncontrollable active infection, including active tuberculosis, HBV DNA level ≥1×103 copies/mL;
Active infections occurred within 72 hours before cleansing; as long as there is no evidence of active infection and antibiotics are not in the list of prohibited drugs, subjects who continue to use preventive antibiotics, antifungal drugs or antiviral drugs are not excluded;
The current systemic use of cyclosporine or steroid drugs such as dexamethasone, recent or current use of inhaled steroids is not excluded;
Renal insufficiency, serum creatinine> 1.6mg/dL (excluding patients with myeloma nephropathy);
Liver insufficiency, aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT)>2.5 times ULN and direct bilirubin>1.5 times ULN;
Hyponatremia, blood sodium <125 mmol/L;
Baseline serum potassium <3.5 mmol/L (potassium supplementation can be given before participating in the study, and serum potassium recovery above this standard is not excluded);
Pregnant or lactating women;
Other serious diseases that may restrict subjects from participating in this trial (such as central nervous system disease, severe heart insufficiency, myocardial obstruction or unstable arrhythmia or unstable angina, gastric ulcer in the past 6 months , Active autoimmune diseases, etc.).